Recently, according to report, Galderma has officially introduced its premium medical skincare brand Alastin to China with the launch of four core products, marking its entry into one of the world’s fastest-growing aesthetic skincare markets. This debut also showcases Alastin’s new premium look and feel, designed to reflect the brand’s leadership in perioperative skincare.
“With Alastin by Galderma, we have a comprehensive perioperative solution to enhance skin recovery around aesthetic treatments and maintenance programs that bring together Galderma’s leading expertise in Dermatological Skincare and Injectable Aesthetics,” said Alan D. Widgerow, Chief Scientific Officer, Galderma, and Head of the Skin Science Center for Innovation.
China’s medical aesthetics market is expected to grow by up to 15% over the next decade. As aesthetic procedures become increasingly mainstream, demand for perioperative skincare is rising, with patients seeking advanced technologies and premium products to optimize treatment outcomes. With its proven efficacy and full-spectrum approach to pre- and post-procedure care, as well as at-home maintenance, Alastin is well positioned to address this growing need.
Professor Yang Bin of the Dermatology Hospital of Southern Medical University noted: “Alastin by Galderma brings a scientifically advanced approach to skin recovery, and I’m excited to see Chinese patients gain access to products that can truly support their skin before and after treatment, and elevate their overall results.”
The China launch comes as Alastin celebrates a decade of innovation and follows robust growth in North America, Latin America, Australia, the UK, and Ireland.
